ECX — Epigenomics AG Cashflow Statement
0.000.00%
Last trade - 00:00- €0.77m
- €10.99m
- €0.34m
Annual cashflow statement for Epigenomics AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | GAS | GAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17 | -11.7 | -2.43 | -17.3 | -4.46 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 3.25 | 0.689 | -1.12 | 1.27 | -2.79 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.245 | 0.894 | -1.02 | -1.61 | 0.189 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -13.5 | -9.57 | -4.15 | -10.6 | -5.71 |
| Capital Expenditures | -0.122 | -0.021 | -0.035 | -0.138 | -0.003 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.169 | 0.024 | 0.996 | 0.097 | 0.071 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.047 | 0.003 | 0.961 | -0.041 | 0.068 |
| Financing Cash Flow Items | — | — | — | -0.019 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 7.12 | 2.98 | 21.6 | -0.45 | -0.057 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -6.33 | -6.59 | 19.5 | -11.1 | -5.7 |